NEWS

TB Vaccine Study in South Africa Shows Promising Preliminary Results
Preliminary results from a study of AERAS-402/Crucell Ad35 show the highest CD8 immune responses ever in a TB vaccine study. Read more

New TB Vaccines Urgently Needed to Fight TB
In the lead up to World TB Day, global efforts to slow the rate of new infections and death from tuberculosis are stalling, according to a new report published today by the WHO. Read more...

Webcast: World TB Day Roundtable Discussion
“TB Today: Old Enemy, New Hurdles”
http://www.kaisernetwork.org/healthcast/tb/24mar08

WHO Report Shows TB Drug Resistance at Highest Ever
New tools, including TB vaccines, are urgently needed to combat the TB epidemic. The WHO reports this week that nearly half a million new cases of multi-drug resistant TB worldwide occur each year and 45 countries report cases of extensively drug-resistant tuberculosis, a virtually untreatable form of the infectious airborne disease. Read More...

WHO Drug Resistance Surveillance Report

Global TB Champion Tours South African TB Vaccine Trial Site
On February 4, 2008, Dr. Marcos Espinal, Executive Secretary of the Stop TB Partnership, toured the primary field site and laboratory facilities of the South African Tuberculosis Vaccine Initiative (SATVI) of the University of Cape Town (UCT), meeting with researchers and clinical trial volunteers. Read more...

Statens Serum Institut, Intercell and Aeras Announce the Start of a TB Vaccine Clinical Trial
On December 4, 2007, SSI, ICLL, and Aeras announce that SSI’s novel prophylactic vaccine HyVac4-IC31 (AERAS-404) against TB have entered Phase I clinical trials in BCG-vaccinated individuals. The clinical trial has been initiated at the Karolinska Institute (Stockholm). Read more...

World AIDS Day
HIV and tuberculosis co-infection is a dual threat that requires a global response.  Yet, TB remains neglected both medically and as a public policy issue.  Read more…

Jerald C. Sadoff, MD Testifies at Senate Hearing
Tuberculosis experts from federal and municipal government agencies, academia and the non-profit product development sector called on the United States Senate to increase support for research and development of new vaccines, diagnostics and medicines in the fight against TB in Washington, DC on October 30, 2007. Read more...

Gates Foundation Grants $200 million to Aeras
On September 18, 2007, the Bill & Melinda Gates Foundation announced a five year grant of $200 million to the Aeras Global TB Vaccine Foundation to conduct clinical trials of up to six TB vaccine candidates. Read more...

Peter M. Small, MD Appointed to Board
The Aeras Global TB Vaccine Foundation, a non-profit organization working through public-private partnerships to develop new vaccines against tuberculosis, announces the appointment of Peter M. Small, MD, to its Board of Directors. Dr. Small has done extensive research in the field of infectious diseases, with a particular focus on tuberculosis. Read more...